Sanofi's Matthew Ros Joins Epizyme
Epizyme Inc. has appointed Matthew Ros chief operating officer (COO). Ros joins the clinical-stage biopharma company from Sanofi, where he was most recently COO, global head of the oncology business unit, overseeing its solid tumour and hematology franchise. Prior to this, he worked within Genzyme’s rare disease business, where he led its second-largest franchise, Pompe disease, as vice president and franchise head. He has also previously served on the board of trustees at CancerCARE.
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.